Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1311) 1311
Book Chapter (42) 42
Dissertation (12) 12
Conference Proceeding (3) 3
Publication (2) 2
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lapatinib (1255) 1255
science & technology (986) 986
life sciences & biomedicine (942) 942
humans (833) 833
oncology (684) 684
female (612) 612
breast cancer (594) 594
trastuzumab (501) 501
breast neoplasms - drug therapy (455) 455
her2 (334) 334
skin and connective tissue diseases (308) 308
receptor, erbb-2 - metabolism (283) 283
cancer (275) 275
breast neoplasms - pathology (273) 273
quinazolines - administration & dosage (265) 265
antineoplastic agents - therapeutic use (259) 259
middle aged (246) 246
tumors (243) 243
receptor, erbb-2 - antagonists & inhibitors (235) 235
quinazolines - therapeutic use (233) 233
cell line, tumor (230) 230
antineoplastic agents (215) 215
antineoplastic combined chemotherapy protocols - therapeutic use (213) 213
breast neoplasms - metabolism (213) 213
quinazolines - pharmacology (207) 207
aged (198) 198
pharmacology & pharmacy (192) 192
biological and medical sciences (190) 190
medical sciences (190) 190
adult (188) 188
animals (187) 187
epidermal growth factor (181) 181
chemotherapy (169) 169
care and treatment (165) 165
antineoplastic agents - pharmacology (162) 162
metastasis (161) 161
treatment outcome (158) 158
receptor, erbb-2 - genetics (154) 154
medicine & public health (140) 140
research (132) 132
breast neoplasms - genetics (130) 130
antimitotic agents (125) 125
quinazolines - adverse effects (124) 124
capecitabine (120) 120
pertuzumab (116) 116
protein kinase inhibitors - pharmacology (115) 115
kinases (113) 113
drug therapy (111) 111
metastatic breast cancer (111) 111
neoplasms (111) 111
pharmacology. drug treatments (107) 107
analysis (106) 106
gynecology. andrology. obstetrics (106) 106
male (106) 106
drug resistance, neoplasm (105) 105
egfr (105) 105
erbb-2 protein (105) 105
mice (105) 105
mammary gland diseases (103) 103
protein kinase inhibitors - therapeutic use (103) 103
tyrosine (102) 102
cancer therapies (95) 95
signal transduction - drug effects (90) 90
drug resistance (88) 88
hematology, oncology and palliative medicine (88) 88
antibodies, monoclonal, humanized (85) 85
cell biology (83) 83
disease-free survival (82) 82
health aspects (82) 82
antineoplastic agents - adverse effects (81) 81
antineoplastic combined chemotherapy protocols - adverse effects (81) 81
clinical trials (81) 81
cell proliferation - drug effects (79) 79
receptor, epidermal growth factor - antagonists & inhibitors (77) 77
apoptosis (76) 76
bevacizumab (74) 74
neoplasm metastasis (74) 74
deoxycytidine - analogs & derivatives (73) 73
antineoplastic agents - administration & dosage (71) 71
biochemistry & molecular biology (70) 70
signal transduction (70) 70
proteins (69) 69
aged, 80 and over (68) 68
antibodies, monoclonal, humanized - therapeutic use (68) 68
antibodies, monoclonal - therapeutic use (65) 65
erbb2 (65) 65
gefitinib (65) 65
apoptosis - drug effects (64) 64
breast neoplasms - mortality (62) 62
deoxycytidine - administration & dosage (62) 62
fluorouracil - analogs & derivatives (61) 61
mutation (61) 61
targeted therapy (61) 61
prognosis (60) 60
quinazolines - pharmacokinetics (60) 60
cancer research (59) 59
erlotinib (59) 59
molecular targeted therapy (59) 59
protein kinase inhibitors - administration & dosage (59) 59
xenograft model antitumor assays (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1319) 1319
French (19) 19
Japanese (15) 15
Chinese (10) 10
German (9) 9
Russian (9) 9
Czech (6) 6
Polish (4) 4
Portuguese (3) 3
Spanish (3) 3
Turkish (3) 3
Hungarian (2) 2
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity
by Shrivastava, Richa and Trivedi, Shruti and Singh, Pankaj Kumar and Asif, Mohammad and Chourasia, Manish Kumar and Khanna, Amit and Bhadauria, Smrati
Biochemical and biophysical research communications, ISSN 0006-291X, 09/2018, Volume 503, Issue 2, pp. 677 - 683
PEGylated liposomes | Lapatinib | Chorioallantoic membrane | HER2 receptor | Biochemistry & Molecular Biology | Biophysics | Life Sciences & Biomedicine | Science & Technology | Apoptosis - drug effects | Humans | Receptor, ErbB-2 - metabolism | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Cardiotoxicity - etiology | Antineoplastic Agents - administration & dosage | Lapatinib - toxicity | Antineoplastic Agents - toxicity | Breast Neoplasms - metabolism | Lapatinib - pharmacology | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Cardiotoxicity - prevention & control | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Lapatinib - therapeutic use | Breast Neoplasms - drug therapy | Chick Embryo | Protein Kinase Inhibitors - administration & dosage | Liposomes - chemistry | Animals | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Kinase Inhibitors - toxicity | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Lapatinib - administration & dosage | Care and treatment | Epidermal growth factor | Polyethylene glycol | Analysis | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells
by Janser, Félice A and Janser, Félice A and Adams, Olivia and Adams, Olivia and Bütler, Vanessa and Schläfli, Anna M and Schläfli, Anna M and Dislich, Bastian and Seiler, Christian A and Seiler, Christian A and Kröll, Dino and Kröll, Dino and Langer, Rupert and Langer, Rupert and Tschan, Mario P and Tschan, Mario P
International journal of molecular sciences, ISSN 1661-6596, 10/2018, Volume 19, Issue 10, p. 3069
Her2 inhibitor | autophagy | esophageal adenocarcinoma | LC3B | OE19 | Lapatinib | p62 | resistance | Her2 | Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
by Ponde, Noam and Ponde, Noam and Bradbury, Ian and Bradbury, Ian and Lambertini, Matteo and Lambertini, Matteo and Ewer, Michael and Ewer, Michael and Campbell, Christine and Campbell, Christine and Ameels, Helene and Ameels, Helene and Zardavas, Dimitrios and Zardavas, Dimitrios and Di Cosimo, Serena and Di Cosimo, Serena and Baselga, José and Baselga, José and Huober, Jens and Huober, Jens and Izquierdo, Miguel and Izquierdo, Miguel and Fumagalli, Debora and Fumagalli, Debora and Bozovic-Spasojevic, Ivana and Bozovic-Spasojevic, Ivana and Maetens, Marion and Maetens, Marion and Harbeck, Nadia and Harbeck, Nadia and Pusztai, Lajos and Pusztai, Lajos and Berghorn, Michael and Berghorn, Michael and Im, Young-Hyuck and Im, Young-Hyuck and Borrego, Manuel Ruiz and Borrego, Manuel Ruiz and Chen, Dar-Ren and Chen, Dar-Ren and Rodeheffer, Richard and Rodeheffer, Richard and Piccart, Martine and Piccart, Martine and Suter, Thomas and Suter, Thomas and de Azambuja, Evandro and de Azambuja, Evandro
Breast cancer research and treatment, ISSN 0167-6806, 4/2018, Volume 168, Issue 3, pp. 631 - 638
Brain natriuretic peptide | Medicine & Public Health | HER2 positive breast cancer | Oncology | Lapatinib | Cardiotoxicity | Troponin T | Life Sciences & Biomedicine | Science & Technology | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Cardiovascular Abnormalities - blood | Cardiotoxicity - pathology | Cardiovascular Abnormalities - pathology | Troponin T - blood | Drug-Related Side Effects and Adverse Reactions | Female | Paclitaxel - administration & dosage | Natriuretic Peptide, Brain - blood | Lapatinib - adverse effects | Cardiotoxicity - blood | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Biomarkers - blood | Breast Neoplasms - drug therapy | Breast Neoplasms - complications | Breast Neoplasms - pathology | Cardiovascular Abnormalities - chemically induced | Breast Neoplasms - blood | Aged | Neoplasm Staging | Lapatinib - administration & dosage | Complications and side effects | Care and treatment | Anthracyclines | Oncology, Experimental | Breast cancer | Research | Biological markers | Cancer | Natriuretic peptides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity
by Vinciguerra, Daniele and Jacobs, Merel and Denis, Stéphanie and Mougin, Julie and Guillaneuf, Yohann and Lazzari, Gianpiero and Zhu, Chen and Mura, Simona and Couvreur, Patrick and Nicolas, Julien
Journal of controlled release, ISSN 0168-3659, 02/2019, Volume 295, pp. 223 - 236
Nanoparticles | Polymer | Drug delivery | Prodrug | Combination therapy | Cancer | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Prodrugs - administration & dosage | Cell Survival - drug effects | Deoxycytidine - chemistry | Nanoparticles - chemistry | Deoxycytidine - administration & dosage | Humans | Lapatinib - chemistry | Polymerization | Deoxycytidine - pharmacology | Doxorubicin - chemistry | Prodrugs - chemistry | Breast Neoplasms - drug therapy | Drug Carriers - chemistry | Drug Synergism | Lapatinib - pharmacology | MCF-7 Cells | Female | Prodrugs - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Drug Combinations | Doxorubicin - administration & dosage | Lapatinib - administration & dosage | Index Medicus | Medicinal Chemistry | Life Sciences | Polymers | Galenic pharmacology | Chemical Sciences | Pharmaceutical sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors
by Coker, Shodeinde A and Hurwitz, Herbert I and Sharma, Sunil and Wang, Ding and Jordaan, Pierre and Zarate, Juan Pablo and Lewis, Lionel D
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2019, Volume 84, Issue 2, pp. 383 - 392
QTc effects | Medicine & Public Health | Oncology | Cancer Research | Advanced cancer patients | Lapatinib | Pharmacology/Toxicology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Lapatinib - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Cross-Over Studies | Lapatinib - pharmacology | Young Adult | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacology | Neoplasms - pathology | Chemotherapy | Pharmacology | Solid tumors | Crossovers | Cancer | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity
by Moon, Jin Young and Han, Ji Min and Seo, Inyoung and Gwak, Hye Sun
Breast cancer research and treatment, ISSN 0167-6806, 11/2019, Volume 178, Issue 1, pp. 239 - 244
Oncology | Lapatinib | Medicine & Public Health | Hepatotoxicity | H2 blocker | CYP3A4 inducer | Life Sciences & Biomedicine | Science & Technology | Multivariate Analysis | Lapatinib - adverse effects | Humans | Risk Factors | Histamine H2 Antagonists - adverse effects | Chemical and Drug Induced Liver Injury - epidemiology | Breast Neoplasms - drug therapy | Cytochrome P-450 CYP3A Inducers - adverse effects | Incidence | Neoplasm Metastasis | Female | Retrospective Studies | Drug Therapy, Combination | Lapatinib - administration & dosage | Aprepitant | Liver cancer | Complications and side effects | Pantoprazole | Liver | Oncology, Experimental | Body weight | Cytochrome P-450 | Metastasis | Research | Risk factors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer
by Agrawal, Satish and Dwivedi, Monika and Ahmad, Hafsa and Chadchan, Sangappa Basanna and Arya, Abhishek and Sikandar, Roshan and Kaushik, Shweta and Mitra, Kalyan and Jha, Rajesh Kumar and Dwivedi, Anil Kumar
Nanomedicine, ISSN 1549-9634, 02/2018, Volume 14, Issue 2, pp. 327 - 337
Nanocrystals | Lapatinib | Hyaluronic acid | Tykerb | Triple-negative breast cancer | Science & Technology - Other Topics | Nanoscience & Nanotechnology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Nanoparticles - chemistry | Lapatinib - chemistry | Hyaluronic Acid - chemistry | Antineoplastic Agents - chemistry | Triple Negative Breast Neoplasms - drug therapy | Lapatinib - pharmacology | Xenograft Model Antitumor Assays | Animals | Triple Negative Breast Neoplasms - metabolism | Triple Negative Breast Neoplasms - pathology | Female | Hyaluronan Receptors - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Mice | Mice, Inbred BALB C | Tumor Cells, Cultured | Antimitotic agents | Breast cancer | Research institutes | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation
by Aimjongjun, Sathid and Mahmud, Zimam and Jiramongkol, Yannasittha and Alasiri, Glowi and Yao, Shang and Yague, Ernesto and Janvilisri, Tavan and Lam, Eric W. -F
BMC cancer, ISSN 1471-2407, 11/2019, Volume 19, Issue 1, pp. 1106 - 1106
Life Sciences & Biomedicine | Oncology | Science & Technology | Cell Survival - drug effects | Lapatinib - adverse effects | Humans | Fibroblasts - pathology | Mice, Knockout | Forkhead Box Protein O3 - genetics | Lapatinib - pharmacology | Sirtuin 2 - genetics | Acetylation - drug effects | Drug Resistance, Neoplasm - genetics | Animals | Nasopharyngeal Carcinoma - genetics | Nasopharyngeal Carcinoma - pathology | Fibroblasts - drug effects | Cell Line, Tumor | Nasopharyngeal Carcinoma - drug therapy | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Proteins | Tyrosine | Care and treatment | Carcinoma | Analysis | Metastasis | Health aspects | Acetates | Vincristine | Cancer | Index Medicus | Nasopharyngeal carcinoma | Lapatinib | Acetylation | FOXO3 | Sirtuin | Chemoresistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays
by Wintgens, Jan P and Wichert, Sven P and Popovic, Luksa and Rossner, Moritz J and Wehr, Michael C
Cellular and molecular life sciences : CMLS, ISSN 1420-682X, 3/2019, Volume 76, Issue 6, pp. 1185 - 1199
Life Sciences | Biomedicine, general | Biochemistry, general | Life Sciences, general | Cell-based assay | Lapatinib | Receptor tyrosine kinases | TEV protease | Split TEV recruitment assay | Cell Biology | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | A549 Cells | Reproducibility of Results | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Humans | ErbB Receptors - genetics | Rats | Biological Assay - methods | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | PC12 Cells | Pyrimidines - metabolism | src Homology Domains | Lapatinib - pharmacology | Animals | Lapatinib - metabolism | Receptor Protein-Tyrosine Kinases - genetics | GRB2 Adaptor Protein - genetics | Protein Binding - drug effects | Cell Line, Tumor | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Acrylamides - metabolism | GRB2 Adaptor Protein - metabolism | Acrylamides - pharmacology | Tyrosine | Epidermal growth factor | Proteases | Detectors | Phenols | Psychotherapy | Cells | Phosphotyrosine | Homeostasis | High-throughput screening | Homology | Antagonists | Neurodevelopmental disorders | Cell interactions | Kinases | Assaying | Recruitment | Proteins | Genetic code | Coding | Growth factors | Adaptor proteins | Cell survival | Hepatocyte growth factor | ErbB protein | Adapters | Pharmacology | Insulin | Grb2 protein | Domains | Ligands | Receptor mechanisms | Biosensors | Adapter proteins | Cancer | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights